NBIX Neurocrine Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NBIX

Price (delayed)

$97.05

Market cap

$9.37B

P/E Ratio

60.28

Dividend/share

N/A

EPS

$1.61

Enterprise value

$9.37B

Neurocrine Biosciences is a publicly traded biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological ...

Highlights
The company's net income has surged by 165% QoQ and by 72% YoY
NBIX's EPS has surged by 164% since the previous quarter and by 69% year-on-year
Neurocrine Biosciences's quick ratio has decreased by 32% YoY but it has increased by 10% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.neurocrine.com/
Peers: RGEN RPRX PFE ANIP

Key stats

What are the main financial stats of NBIX
Market
Shares outstanding
96.59M
Market cap
$9.37B
Enterprise value
$9.37B
Valuations
Price to earnings (P/E)
60.28
Price to book (P/B)
5.46
Price to sales (P/S)
6.25
EV/EBIT
42.42
EV/EBITDA
39.62
EV/Sales
6.3
Earnings
Revenue
$1.49B
EBIT
$221M
EBITDA
$236.6M
Free cash flow
$322.9M
Per share
EPS
$1.61
Free cash flow per share
$3.37
Book value per share
$17.76
Revenue per share
$15.54
TBVPS
$24.34
Balance sheet
Total assets
$2.37B
Total liabilities
$660.9M
Debt
$262.9M
Equity
$1.71B
Working capital
$915.8M
Liquidity
Debt to equity
0.15
Current ratio
2.7
Quick ratio
2.49
Net debt/EBITDA
N/A
Margins
EBITDA margin
15.9%
Gross margin
98.4%
Net margin
10.4%
Operating margin
16.7%
Efficiency
Return on assets
7.1%
Return on equity
10.2%
Return on invested capital
11.9%
Return on capital employed
12.1%
Return on sales
14.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NBIX stock price

How has the Neurocrine Biosciences stock price performed over time
Intraday
0%
1 week
-0.16%
1 month
-5.04%
1 year
3.55%
YTD
-18.75%
QTD
-18.75%

Financial performance

How have Neurocrine Biosciences's revenue and profit performed over time
Revenue
$1.49B
Gross profit
$1.47B
Operating income
$249M
Net income
$154.5M
Gross margin
98.4%
Net margin
10.4%
The company's net income has surged by 165% QoQ and by 72% YoY
The net margin has soared by 148% QoQ and by 32% YoY
The operating income has surged by 143% year-on-year and by 128% since the previous quarter
The operating margin has soared by 111% from the previous quarter and by 86% YoY

Growth

What is Neurocrine Biosciences's growth rate over time

Valuation

What is Neurocrine Biosciences stock price valuation
P/E
60.28
P/B
5.46
P/S
6.25
EV/EBIT
42.42
EV/EBITDA
39.62
EV/Sales
6.3
NBIX's EPS has surged by 164% since the previous quarter and by 69% year-on-year
The price to earnings (P/E) is 79% lower than the last 4 quarters average of 280.4 and 75% lower than the 5-year quarterly average of 242.3
NBIX's price to book (P/B) is 56% lower than its 5-year quarterly average of 12.3 and 17% lower than its last 4 quarters average of 6.6
The company's equity rose by 24% YoY and by 11% QoQ
The stock's price to sales (P/S) is 51% less than its 5-year quarterly average of 12.7 and 16% less than its last 4 quarters average of 7.4
Neurocrine Biosciences's revenue has increased by 31% YoY and by 7% QoQ

Efficiency

How efficient is Neurocrine Biosciences business performance
Neurocrine Biosciences's return on assets has surged by 154% QoQ and by 58% YoY
The ROE has soared by 149% from the previous quarter and by 48% YoY
The company's return on invested capital has surged by 138% QoQ and by 72% YoY
NBIX's return on sales has surged by 118% since the previous quarter and by 32% year-on-year

Dividends

What is NBIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NBIX.

Financial health

How did Neurocrine Biosciences financials performed over time
The company's current ratio fell by 32% YoY but it rose by 8% QoQ
Neurocrine Biosciences's quick ratio has decreased by 32% YoY but it has increased by 10% from the previous quarter
The debt is 85% lower than the equity
NBIX's debt to equity has dropped by 53% year-on-year and by 12% since the previous quarter
The debt is down by 40% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.